Trial Profile
A study comparing efficacy of Ranibizumab and Aflibercept in patients with neovascular age related macular degeneration.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 22 May 2017 New trial record